Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol
Go back to Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol| ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) | Delayed: 30.11 +1.12 (3.86%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.99 | 52 Week High | $5.17 | |||
| Open | $29.57 | 52 Week Low | $0.94 | |||
| Day High | $30.70 | P/E | N/A | |||
| Day Low | $28.41 | EPS | $0.00 | |||
| Volume | 5,083,018 | |||||
